Lexicon Pharmaceuticals Inc (LXRX)
0.7147
-0.01
(-1.23%)
USD |
NASDAQ |
Dec 20, 16:00
0.6498
-0.06
(-9.08%)
After-Hours: 05:41
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 258.36M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -41.42% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 39.74 |
| Price to Book Value | 1.447 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5596 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 94.56% |
Profile
| Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |
| URL | https://www.lexpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 02, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |
| URL | https://www.lexpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 02, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |